MEK signaling represents a viable therapeutic vulnerability of KRAS-driven somatic brain arteriovenous malformations
Carlos Perfecto Flores Suarez, Omar Ashraf Harb, Ariadna Robledo, Gabrielle E. Largoza, John J. Ahn, Emily K. Alley, Ting Wu, Surabi Veeraragavan, Samuel T. McClugage, Ionela Iacobas, Jason E. Fish, Peter Tze Man Kan, Sean P. Marrelli, Joshua D. Wythe
This study shows that KRAS mutations drive brain arteriovenous malformations (bAVMs) in specific brain regions and that MEK inhibition can reduce their severity in mice, suggesting a potential therapeutic approach for human bAVMs.
bioRxiv · May 15, 2024 · PreprintMolecular Biology